Eli Lilly LLY Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 82.8%+1.1pp | 83%+1.7pp | 83%+2.1pp | 82.6%+1.9pp | 81.7%+1.5pp | |
| Net margin | 35%+12.3pp | 31.7%+8.2pp | 31%+10.5pp | 25.9%+7.0pp | 22.7%+5.6pp | |
| EBITDA margin | 45.9%+14.4pp | 42.5%+10.5pp | 41.1%+12.1pp | 35.2%+8.0pp | 31.5%+6.1pp | |
| Free cash flow margin | 16.4%+8.7pp | 13.8%+5.4pp | 15.6%— | 9.2%— | 7.6%— | |
| Returns | ||||||
| Return on equity | 107.6%+29.9pp | 101.2%+16.6pp | 96.8%+31.1pp | 86.7%+27.1pp | 77.7%+26.6pp | |
| Return on assets | 24.5%+10.1pp | 21.6%+6.8pp | 19.3%+6.8pp | 16%+4.4pp | 14.5%+4.0pp | |
| Return on invested capital | 42%+16.6pp | 38.3%+11.8pp | 37.4%+13.8pp | 29.4%+7.2pp | 25.3%+5.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×+0.1× | 0.7×+0.1× | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | |
| Inventory turnover | 1×-0.1× | 1×-0.2× | 1×-0.2× | 1.1×-0.3× | 1.2×-0.2× | |
| Liquidity | ||||||
| Current ratio | 1.5×+0.1× | 1.6×+0.4× | 1.5×+0.3× | 1.3×+0.2× | 1.4×0.0× | |
| Quick ratio | 1.1×0.0× | 1.2×+0.3× | 1.2×+0.3× | 1×+0.1× | 1.1×0.0× | |
| Cash ratio | 0.1×0.0× | 0.2×+0.1× | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 1.4×-1.1× | 1.6×-0.8× | 1.8×-0.4× | 2.2×+0.1× | 2.4×+0.4× | |
| Debt-to-assets | 0.4×-0.1× | 0.4×-0.1× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Net debt / EBITDA | 1.1×-1.1× | 1.3×-0.9× | 1.3×-1.0× | 1.9×-0.5× | 2.3×-0.3× | |
| Per Share | ||||||
| Book value per share | $34.82+98.9% | $29.51+86.9% | $26.47+68.2% | $20.31+35.4% | $17.50+23.5% | |
| Valuation | ||||||
| Market capitalization | $821.68B+10.8% | $961.86B+38.5% | $684B-14.3% | $698.51B-14.4% | $741.66B+5.8% | |
| Enterprise value | $859.77B+10.6% | $997.32B+37.4% | $716.71B-13.2% | $735.04B-12.6% | $777.08B+7.3% | |
| Price / earnings | 32.5×-34.3× | 46.6×-19.0× | 37.1×-58.2× | 50.6×-60.5× | 66.8×-47.4× | |
| Price / sales | 11.4×-3.8× | 14.8×-0.7× | 11.5×-8.0× | 13.1×-7.8× | 15.1×-4.4× | |
| Price / book | 26.3×-20.7× | 36.2×-12.4× | 28.7×-27.3× | 38.2×-21.9× | 47×-7.7× | |
| EV / EBITDA | 25.9×-24.4× | 36×-14.3× | 29.4×-40.5× | 39.2×-40.1× | 50.4×-29.0× | |
| EV / sales | 11.9×-4.0× | 15.3×-0.8× | 12.1×-8.1× | 13.8×-7.8× | 15.9×-4.3× | |
| Free cash flow yield | 1.4%+0.9pp | 0.9%+0.4pp | 1.4%— | 0.7%— | 0.5%— | |
| Earnings yield | 3.1%+1.6pp | 2.1%+0.6pp | 2.7%+1.6pp | 2%+1.1pp | 1.5%+0.6pp | |
| Dividend yield | 0.7%0.0pp | 0.6%-0.1pp | 0.8%+0.2pp | 0.7%+0.2pp | 0.7%+0.1pp | |
| PEG ratio | 0.3×-0.6× | 0.5×-0.2× | 0.3×-1.1× | 0.6×-8.0× | 0.8×-13.6× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Eli Lilly's ratios come from?
- Every ratio is computed from Eli Lilly's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
